Asahi Kasei Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AHKSY research report →
Price Chart
About the company
Asahi Kasei Corporation, a multinational enterprise established in Tokyo, Japan, in 1922, engages globally in the manufacturing, processing, and sale of a diverse array of products across three primary business segments: Material, Homes, and Health Care. Its expansive Material segment encompasses a broad spectrum of chemical products and functional materials. This includes foundational chemicals like caustic soda, nitric acid, ammonia, acrylonitrile, and styrene, as well as various chemical fertilizers, intermediates, polymers, and additives.
- CEO
- Koshiro Kudo
- IPO
- 2007
- Employees
- 47,895
- HQ
- Tokyo, TY, JP
Get TickerSpark's AI analysis on AHKSY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.72B
- P/E
- 11.20
- Fwd P/E
- 0.08
- PEG
- 0.18
- P/S
- 0.68
- P/B
- 1.02
- EV/EBITDA
- 6.06
- Div Yield
- 2.76%
- Gross Margin
- 33.47%
- Op Margin
- 8.19%
- Net Margin
- 6.10%
- ROE
- 9.51%
- ROIC
- 5.03%
Latest fiscal year · YoY change
- Revenue
- $3.26T+7.3%
- Gross Profit
- $1.07T+11.6%
- Op Income
- $245.14B
- Net Income
- $168.37B+24.7%
- EPS
- $247.66+26.4%
- OCF Growth
- +6.6%
- FCF Growth
- +38.9%
- 52W High
- $24.12
- 52W Low
- $15.18
- 50D MA
- $20.76
- 200D MA
- $20.83
- Beta
- 0.59
- RSI (14)
- 44
- Avg Volume
- 32.93K
No earnings-call transcripts are available for AHKSY yet.
- Free Float
- 97.2%
- Shares Outstanding
- 673.12M
- Float Shares
- 654.26M
Congressional trading
Senate and House stock disclosures for AHKSY, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Our AHKSY coverage
Recent articles, reports, and earnings notes.
No research on AHKSY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AHKSY report →Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients
businesswire.com · Oct 8
Asahi Kasei to Integrate Global Pharmaceutical Brand Under Asahi Kasei Therapeutics
businesswire.com · Sep 29
Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing
businesswire.com · Sep 15
Asahi Kasei Unveils New Wet-Process Separator Coating Line in North Carolina, Advancing the Company's 40-Year North American Battery Separator Strategy
businesswire.com · Aug 26
Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries
businesswire.com · Aug 19
Asahi Kasei's Capacity Expansion for Water Electrolysis and Chlor‑Alkali Equipment in Kawasaki Awarded Regional Economic Incentives
businesswire.com · Aug 19
Asahi Kasei Enters First License Agreement for Production and Sale of Acetolyte™ Novel Electrolyte in China
businesswire.com · Aug 6
Asahi Kasei's Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time
businesswire.com · Jun 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.